Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 702.

https://doi.org/10.1182/blood-2023-180720

Published: 2023

Journal Articles

Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia

Georgina L Ryland, Ashish Bajel, Michael Dickinson, Paul G Ekert, Oliver Hofmann, Maarten IJzerman, Ashley P Ng, Alicia Oshlack, Breon Schmidt, Ing S Tiong, Martin Vu, David Alan Westerman, Sean Grimmond, Piers Blombery

Blood (2021) 138 (Supplement 1): 274.

https://doi.org/10.1182/blood-2021-146396

Published: 2021

Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2021-147335

Published: 2021

Journal Articles

Mutational and Copy Number Profiling of Circulating Tumor DNA in Acute Myeloid Leukemia Using Targeted Next Generation Sequencing

Ing Soo Tiong, MBBS,FRACP,FRCPA, Clarissa Wilson, BSc,MSc, Satwica Yerneni, MS, John Markham, Karen Dun, BSc,FHGSA, Ashish Bajel, FRACP, Ella R Thompson, PhD BSc, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138933

Published: 2020

Journal Articles

A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Adrian Minson, MBBS,FRACP,FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, David Ritchie, MB ChB, PhD FRACP, FRCPA, Piers Blombery, MBBS, John F. Seymour, Constantine S. Tam, MBBS, Michael Dickinson, DMed Sci

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138946

Published: 2020

Journal Articles

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

Ella R Thompson, PhD BSc, Tamia Nguyen, Yamuna Kankanige, PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Rachel Thijssen, PhD, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS, MD, John F. Seymour, Andrew W Roberts, MBBS, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137411

Published: 2020

Journal Articles

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Ella R Thompson, PhD BSc, Xiangting Chen, PhD, Tamia Nguyen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, John F. Seymour, Constantine S. Tam, MBBS, MD, Michael A Dengler, PhD, David C.S. Huang, MBBS MRCP PhD, Andrew Wei, MBBS,PhD, Andrew W Roberts, MBBS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137775

Published: 2020

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Blood (2019) 134 (Supplement_1): 170.

https://doi.org/10.1182/blood-2019-125488

Published: 2019

Journal Articles

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, MBBS, Ella Thompson, PhD BSc, Tamia Nguyen, Xiangting Chen, PhD, Michelle McBean, Richard W Birkinshaw, PhD, Peter E Czabotar, PhD, Rachel Thijssen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, John F. Seymour, MBBS, PhD FRACP, David Alan Westerman, MBBS, FRCPA, FRACP, David C.S. Huang, MBBS MRCP PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 171.

https://doi.org/10.1182/blood-2019-125457

Published: 2019

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, MBBS, Jennifer Lickiss, MSc, BSc, Yamuna Kankanige, Satwica Yerneni, MS, John Markham, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Diego Villa, MD MPH, Graham W Slack, MD, Collin Chin, MBBS, Constantine S. Tam, MBBS (Hons), MD, Stephen Lade, MBBS, FRCPA, Niles Elizabeth Nelson, BSc, MBBS, Paul J Neeson, BSc, PhD, John F. Seymour, MBBS, PhD FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 4290.

https://doi.org/10.1182/blood-2019-127800

Published: 2019

Journal Articles

Cnspectorx - Copy Number Assessment at a Genome Level from Targeted Sequence Data Optimized for Hematological Malignancy

John Markham, Satwica Yerneni, MS, Georgina L Ryland, Andrew Fellowes, PhD, Ella Thompson, PhD BSc, Stephen Fox, David Alan Westerman, MBBS, FRCPA, FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, Anthony Papenfuss, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 3378.

https://doi.org/10.1182/blood-2019-125471

Published: 2019

Journal Articles

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Jianan Gong, PhD, Rachel Thijssen, Richard W Birkinshaw, PhD, Ella Thompson, PhD, Charis E Teh, PhD, Tamia Nguyen, Zhen Xu, PhD, Christoffer Flensburg, PhD, Thomas Lew, MBBS, Ian Majewski, PhD, Daniel Gray, David Alan Westerman, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, John F. Seymour, MBBS, PhD, Peter E Czabotar, PhD, David Huang, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): LBA-7.

https://doi.org/10.1182/blood-2018-120761

Published: 2018

Journal Articles

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Max Wolf, FRACP, FRCPA, MBBS, Surender Juneja, MD, David Alan Westerman, MBBS, FRCPA, FRACP, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1876.

https://doi.org/10.1182/blood-2018-99-114048

Published: 2018

Journal Articles

TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy

David Alan Westerman, MBBS, FRACP, FRCPA, Giada Zapparoli, Chelsee Hewitt, Kevin Lynch, MBBS, Linda Mileshkin, Emma Link, PhD, Alexander Dobrovic, H. Miles Prince

Blood (2010) 116 (21): 4046.

https://doi.org/10.1182/blood.V116.21.4046.4046

Published: 2010

Journal Articles

Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients

Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Lisa Demosthenous, Glen Wiesner, PhD, Emma Link, PhD, David Alan Westerman, MBBS, FRACP, FRCPA, Neil Came, MBBS, FRACP, FRCPA, John F Seymour, MD, FRACP, PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2010) 116 (21): 2256.

https://doi.org/10.1182/blood.V116.21.2256.2256

Published: 2010

Journal Articles

The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study

Kirsten Herbert, MBBS, FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Dennis Carney, MBBS, FRACP, FRCPA, David Alan Westerman, MBBS, FRACP, FRCPA, Henry Januszewicz, MBBS, FRACP, FRCPA, Simon Harrison, MBBS, PhD, David Ritchie, MBChB, FRACP, FRCPA, PhD, H. Miles Prince, John Francis Seymour, MBBS, FRACP, PhD

Blood (2008) 112 (11): 3596.

https://doi.org/10.1182/blood.V112.11.3596.3596

Published: 2008

Journal Articles

A Prospective Study of the Prognostic Impact of 18 [F]-FDG-PET and Molecular Response in Patients with Relapsed Indolent Non-Hodgkin Lymphoma (NHL) Following Iodine-131-Rituximab Radio-Immunotherapy (RIT).

Mark J. Bishton, MB, ChB, Rod Hicks, David Alan Westerman, Miles Prince, Max Wolf, John Francis Seymour

Blood (2007) 110 (11): 3421.

https://doi.org/10.1182/blood.V110.11.3421.3421

Published: 2007

Journal Articles

Ancestim (SCF) and High-Dose Twice-Daily Filgrastim (G-CSF) Is Superior to G-CSF Alone or Cyclophosphamide Plus G-CSF for Mobilization of Peripheral Blood Stem Cells (PBSC) in Patients with Indolent Lymphoproliferative Disorders Previously Treated with Fludarabine; Results of a Historically-Controlled Phase-II Study.

John Francis Seymour, MB, BS, PhD, Sue Morgan, MB BS, Miles Prince, MB BS MD, David Alan Westerman, MB BS, Max M. Wolf, MB BS, Dennis A. Carney, MB BS, Kally Yuen, MSc

Blood (2006) 108 (11): 3066.

https://doi.org/10.1182/blood.V108.11.3066.3066

Published: 2006

NARROW

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Mutational and Copy Number Profiling of Circulating Tumor DNA in Acute Myeloid Leukemia Using Targeted Next Generation Sequencing

A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)

High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia

BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Cnspectorx - Copy Number Assessment at a Genome Level from Targeted Sequence Data Optimized for Hematological Malignancy

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy

Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients

The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study

A Prospective Study of the Prognostic Impact of 18 [F]-FDG-PET and Molecular Response in Patients with Relapsed Indolent Non-Hodgkin Lymphoma (NHL) Following Iodine-131-Rituximab Radio-Immunotherapy (RIT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only